Abstract 1935P
Background
The tertiary lymphoid structure (TLS) is an important part of the tumor microenvironment. It generates circulating immune cells and inhibits tumor growth and progression, which is closely related to the efficacy of immunotherapy.
Methods
This study collected the transcriptome information and clinical data of 10327 tumor samples and 730 normal samples of 33 cancer types from the TCGA database. Based on previous literature, three sets of TLS-related gene sets were selected and merged into the total TLS gene set. The TLS enrichment scores were calculated by the GSVA algorithm. Further, utilize TIMER 2.0 and CIBERSORTNE algorithms to analyze the distribution of tumor-infiltrating immune cells. Based on the enrichment score of TLS, sarcoma patients were divided into three TLS subtypes via the "hclust" R package. TLS-related prognostic core genes were screened via Lasso Cox and multivariate Cox regression and further used to establish the TLS-related prognostic signature. The public immunotherapy cohorts and our center immunotherapy patients were used to validate the efficacy of immunotherapy.
Results
The TLS gene set enrichment score established in this study is significantly positively correlated with immune cell infiltration such as T cells, B cells, and DC cells, which can reflect the TLS status in tumor tissue. Kaplan Meier survival analysis showed that patients with high TLS had better overall survival and progression-free survival compared to patients with low TLS. Through Lasso Cox and multivariate Cox regression, two TLS-related prognostic core genes (TNFRSF14 and DUSP9) were ultimately screened, and a TLS-related prognostic signature was established. Immunohistochemistry showed that the expression of TNFRSF14 was increased and the expression of DUSP9 was reduced in patients with soft tissue sarcoma who achieved optimal immunotherapy.
Conclusions
The TLS-Total gene set, TLS-related prognostic signature, TNFRSF14, and DUSP9 selected in this study can predict the prognosis of patients with soft tissue sarcoma. TNFRSF14 and DUSP9 are associated with immune cell infiltration, which can indicate the efficacy of immunotherapy and may become new predictive markers of immunotherapy efficacy.
Clinical trial identification
No
Editorial acknowledgement
No
Legal entity responsible for the study
The authors.
Funding
Natural Science Basic Research Program of Shaanxi (No. 2021JZ-35).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1960P - Clinical outcomes of the patients with alveolar soft part sarcoma developed brain metastasis
Presenter: Yu Toda
Session: Poster session 15
1961P - Prevalence of diagnostic discrepancies in soft tissue and bone tumors from initial diagnosis to referral center
Presenter: Khomsit Thongthammachat
Session: Poster session 15
1963P - Comprehensive profiling of chordoma reveals tumor microenvironment subtypes and unique molecular findings
Presenter: Marina Voropaeva
Session: Poster session 15
1964P - Biomimetics of three-dimensional (3D) osteosarcoma (OS) models: A scoping review
Presenter: Vinesh Sandhu
Session: Poster session 15
1965P - Transcriptional analysis of immune microenvironment of chordomas of the skull base and mobile spine
Presenter: Jason Roszik
Session: Poster session 15
1966P - Extending the interval of denosumab treatment for unresectable giant cell tumor of bone
Presenter: Toshiyuki Kunisada
Session: Poster session 15
1967P - A single-arm multicenter trial of the combination of anlotinib with chemotherapy in patients with stage IIb classic osteosarcoma of the extremity
Presenter: Fan Tang
Session: Poster session 15
1968P - Metastatic Ewing sarcoma, patterns of care and outcomes of patients in a real-life setting: The Metabone national observational study
Presenter: coline ducrot
Session: Poster session 15
1969P - Intratumoral immune infiltrates in chondrosarcoma (ChS)
Presenter: Piotr Rutkowski
Session: Poster session 15
1970P - Metastatic chondrosarcoma, patterns of care and outcomes of patients in a real-life setting: The Metabone national observational study
Presenter: coline ducrot
Session: Poster session 15